Why the study?
Data were limited regarding the effects of the choice of intravenous vasoactive medication on in-hospital mortality in patients hospitalized with ADHF.
Does treatment with intravenous vasodilators (nitroglycerin or nesiritide) compared to positive inotropes (dobutamine or milrinone) reduce in-hospital mortality in patients hospitalized with acute decompensated heart failure?
Population
15,230 patients hospitalized with ADHF receiving intravenous vasoactive medications
Comparison
Nitroglycerin vs nesiritide vs milrinone vs dobutamine
Design
Retrospective analysis of multicenter registry data
Key result
Intravenous nitroglycerin was associated with lower in-hospital mortality compared to milrinone (OR 0.69; 95% CI 0.53-0.89; p<=0.005) in patients with acute decompensated heart failure.
Authors
Loading...
Should not yet change practice favoring vasodilators over inotropes in ADHF; leaves open causality due to observational design.
Observational (n=15,230)
Yes
Does treatment with intravenous vasodilators (nitroglycerin or nesiritide) compared to positive inotropes (dobutamine or milrinone) reduce in-hospital mortality in patients hospitalized with acute decompensated heart failure?
Effect estimate: OR 0.69 (95% CI 0.53-0.89)
p-value: p=<=0.005
In patients with acute decompensated heart failure, the use of intravenous vasodilators (nitroglycerin or nesiritide) is associated with significantly lower in-hospital mortality compared to positive inotropes (dobutamine or milrinone).
Abraham et al. (2005) conducted an observational in Acute decompensated heart failure (n=15,230). Intravenous nitroglycerin or nesiritide vs. Intravenous milrinone or dobutamine was evaluated on In-hospital mortality (OR 0.69, 95% CI 0.53-0.89, p=<=0.005). Intravenous nitroglycerin was associated with lower in-hospital mortality compared to milrinone (OR 0.69; 95% CI 0.53-0.89; p<=0.005) in patients with acute decompensated heart failure.